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ABSTRACT
CONTEXT AND OBJECTIVE: Differences in human papillomavirus (HPV) types may correlate with the biological potential and invasion risk of high-grade 
cervical intraepithelial neoplasia (CIN 2 and CIN 3). The objective of this study was to determine the relationship between different combinations of HPV 
types and CIN severity. 
DESIGN AND SETTING: Cross-sectional study, at Universidade Estadual de Campinas (Unicamp).
METHODS: Cervical samples from 106 women treated due to CIN 2 (18) or CIN 3 (88) were examined for specific HPV genotypes using Roche Linear 
Array® (LA-HPV). The proportions of CIN 2 and CIN 3 in groups of women infected with the HPV phylogenetic groups A7 and A9 were compared. Three 
groups were formed: women with single infections; multiple infections; and the whole sample. 
RESULTS: Multiple infections were detected in 68 samples (64.7%). The most frequent high-risk genotypes detected (single/multiple) were HPV 16 
(57.1%), HPV 58 (24.7%), HPV 33 (15.2%), HPV 52 (13.3%), HPV 31 (10.4%), HPV 51 (7.6%) and HPV 18 (6.6%). Women without infection with HPV 
species Alpha 9 were less likely to have CIN 3 than were their Alpha 9 HPV-infected counterparts. HPV 16 and/or HPV 18, with or without associations 
with other viral types, were more frequently found in women with CIN 3 than in those with CIN 2. 
CONCLUSIONS: The severity of high-grade CIN may be aggravated by the presence of HPV types included in the Alpha 9 phylogenetic classification and by 
infections including HPV 16 and 18, singly or in combination with other HPV genotypes. 
RESUMO
CONTEXTO E OBJETIVO: Diferentes tipos de papilomavírus humano (human papillomavirus, HPV) podem ser correlacionados com a capacidade biológica e 
risco de invasão das neoplasias intra-epitelial de alto grau cervical (NIC 2 e NIC 3). O objetivo deste estudo foi determinar a relação de diferentes tipos 
de HPV com a gravidade da NIC. 
TIPO DE ESTUDO E LOCAL: Estudo transversal na Universidade Estadual de Campinas (Unicamp).
MÉTODOS: Foram avaliados os genótipos específicos de HPV da amostra cervical de 106 mulheres com NIC 2 (18) ou NIC 3 (88), utilizando Roche Linear 
Array® (LA) HPV genotyping assay. Foram comparadas as proporções de NIC 2 e NIC 3 em grupos de mulheres infectadas com tipos de HPV dos grupos 
filogenéticos A7 e A9. Três grupos foram formados: mulheres com infecção simples; infecção múltipla; e infecção simples e múltipla. 
RESULTADOS: Infecções múltiplas foram detectadas em 68 (64,7%) das amostras. Os genótipos de alto risco mais frequentemente detectados em infecção 
simples ou múltipla foram HPV 16 (57,1%), HPV 58 (24,7%), HPV 33 (15,2%), HPV 52 (13,3%), HPV 31 (10,4%), HPV 51 (7,6%) e HPV 18 (6,6%). A 
probabilidade de mulheres com NIC 3 serem infectadas com HPV que não da espécie Alfa 9 era menor do que com os tipos de HPV da espécie Alfa 9. HPV 
16 e ou 18, associado ou não com outros tipos virais eram mais frequentemente encontrados nas mulheres com NIC 3 do que naquelas com NIC 2.
CONCLUSÃO: A gravidade da NIC de alto grau pode ser aumentada pela presença de tipos de HPV incluídos na classificação filogenética Alfa 9 e por 
infecções que incluem HPV 16 e 18 combinados ou não com outros genótipos de HPV.
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INTRODUCTION
Persistent infection with high-risk types of human papillomavirus 
(HPV) is known to be a unifying risk factor for the development of cervi-
cal intraepithelial neoplasia (CIN) and invasive carcinoma.1-4 CIN is clas-
sified into three grades, based on progressive spreading of atypical cells 
from the proliferative layers to the full thickness of the epithelium.5 Al-
though CIN 2 and CIN 3 represent high-grade lesions of the cervix, they 
are heterogeneous in their potential for progression to invasive cancer.6
Current evidence indicates that differences in HPV types may cor-
relate with the biological potential and invasion risk of CIN lesions.2,7,8 
Recent data show that the HPV types found in CIN 2 are different 
from those observed in CIN 3, and CIN 2 frequently contains HPV 
types that are not commonly found as single types in invasive cancers.9 
This could suggest that invasive cancer is unlikely to be the end point 
for such CIN 2 lesions.9,10
Genital HPV types are classified as Alpha papillomavirus genera. 
The species within these genera are closely related in terms of phylo-
genesis. Despite having distinct genomic sequences, they show identi-
cal or very similar biological or pathological properties. Along with the 
type species HPV 16, species 9 also includes HPV types 31, 33, 35, 52, 
58 and 67. Along with the type species HPV 18, species 7 also includes 
HPV types 39, 45, 59, 68, 70 and 85.11
Controversy exists regarding possible competition or synergy of in-
dividual types in multiple infections. Some natural history studies have 
suggested that women who are already infected present greater risk of 
acquiring new HPV types than do those who are HPV-negative.12,13 An 
alternative interpretation of these findings might be that more than one 
HPV type is transmitted simultaneously, and their sequential detection 
could be a consequence of replicated life cycles that are asynchronous 
and only occasionally overlap.14 These life cycles might be interdepen-
dent.15 Multiple HPV types may be associated with a risk of progres-
sion that exceeds the risk due to single-type infections. In a recent study, 
there was evidence that this risk increased with the cumulative number 
of HPV types, in most combinations, and these associations seemed 
particularly strong over the short term.16
OBJECTIVE
In this report, our prime focus was to address the question of het-
erogeneity of HPV types as a possible source of biological variation in 
CIN 2 and CIN 3. To add new information to the growing body of lit-
erature in women with these lesions, we aimed to evaluate the distribu-
tion of single and multiple infections of different HPV types in women 
with high-grade cervical intraepithelial neoplasia (CIN 2 and CIN 3), 
and to compare the prevalence of different HPV types in CIN 2 and 
CIN 3, in view of the phylogenetic classification of the virus.
METHODS
Type of study and setting
The patient sample for this cross-sectional study comprised 106 
non-consecutive women who underwent large loop excision of the 
transformation zone (LLETZ) to treat CIN 2 or 3, between February 
2001 and April 2004.
The study was carried out at the colposcopy clinics of Universidade 
Estadual de Campinas (Unicamp), Brazil, a public health institution 
dedicated to comprehensive care for women. 
Sample
The sample size for this study was estimated according to the re-
lationship n = (p*q)/E2, where n is the sample size, p is the estimated 
prevalence of the condition in affected women (in the present case, 
the prevalence of HPV in high-grade CIN is as high as 95%16), and q 
is the prevalence of the condition in non-affected subjects. The overall 
prevalence of highly oncogenic types of HPV in an urban female pop-
ulation (mean age: 33 years) without high-grade CIN has been esti-
mated as 6.2%.16 E is the standard error, set to 2.5% for the present cal-
culations. Therefore, we estimated a sample size of roughly 94 women.
The women in this study were selected after referral to Unicamp 
for specialized treatment for high-grade squamous intraepithelial lesions 
(HSIL). They were invited to enter the study at the time of their pre-
treatment visit (i.e. their first visit after being accepted for treatment). 
One of the researchers was always present at these visits and, after ex-
plaining the study protocol and ethical concerns, made the invitation. 
All the patients who agreed to be enrolled in the study gave their writ-
ten signed consent.
At the pretreatment visit, all of the women were interviewed to ob-
tain clinical, social and demographic data. A complete gynecological ex-
amination was performed, with collection of endocervical specimens for 
HPV testing, followed by colposcopic examination of the cervix. The de-
cision to perform diathermal conization was based on the referral cytolo-
gy and the clinical/colposcopic configuration of the cervix. The study was 
approved by the local Ethics Committee (Protocol #CEP 309/2004). 
Procedures
Histology
The histological samples consisted of 106 diathermal conization 
specimens. This material was fixed in 10% phosphate buffered formalin 
and then was embedded in paraffin and stained with hematoxylin and 
eosin. The samples were analyzed according to the World Health Orga-
nization’s criteria.17 In the present series, only cases diagnosed as CIN 2 
(n = 18) or CIN 3 (n = 88) were included. The patients’ mean age was 
34.08 years (90% central range: 17.5 to 73.6 years). The ages of the 
women with CIN 2 (mean age: 32.01 years; 90% central range: 17.4 to 
59.5 years) and CIN 3 (mean age: 34.05 years; 90% central range: 17.3 




For HPV typing, cervical cells were collected using a Digene™ cervi-
cal brush and were then shaken in universal collection medium (UCM). 
An aliquot of 200 μl of UCM was sampled (Digene Corporation, United 
States) and centrifuged at 13,000 g for 10 minutes. The supernatant was 
removed and the cell pellet was stored at -20 °C until further use. The 
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HPV genotype
Overall prevalence of HPV genotypes 





16 60 (57.1) 16 (15.2)
58 26 (24.7) 6 (5.7)
33 16 (15.2) 4 (3.8)
52 14 (13.3) 1 (0.9)
31 11 (10.4) 2 (1.9)
51 8 (7.6) 1 (0.9)
18 7 (6.6) 0
68 7 (6.6) 0
35 6 (5.7) 1 (0.9)
45 5 (4.7) 0
56 4 (3.8) 1 (0.9)
39 3 (2.8) 0
59 3 (2.8) 0
66 3 (2.8) 1 (0.9)
82 3 (2.8) 0
73 2 (1.9) 0
Intermediate risk
53 2 (1.9) 0
26 0 0
Low risk
70 5 (4.7) 1 (0.9)
CP6108 5 (4.7) 0
61 4 (3.8) 0
67 3 (2.8) 0
81 3 (2.8) 0
54 2 (1.9) 0
6 2 (1.9) 1 (0.9)
11 1 (0.9) 1 (0.9)
40 1 (0.9) 0
42 1 (0.9) 0
72 1 (0.9) 0
Not classified
71 5 (4.7) 0
55 2 (1.9) 0
62 2 (1.9) 0





Table 1. Distribution of human papillomavirus (HPV) genotypes in single 
and multiple infections in Brazilian women
cells in the pellet were re-suspended in 200 μl of digestion solution (Tris 1 
mM, 200 μg/ml of proteinase K and 0.5% sodium dodecyl sulfate, SDS). 
This suspension was shaken and incubated at 55 °C for two hours and at 
95 °C for five minutes. Next, 200 μl of solution phenol/chloroform/iso-
amyl alcohol (25:24:1) was added and shaken vigorously before centrifu-
gation at 5,000 g for 10 minutes. The aqueous phase was removed and 
transferred to a clean tube, and 1/10 (10%) of NaAc (sodium acetate) 3M 
pH 5.2 was added and mixed. Next, 2.5 volumes of 70% ice-cold etha-
nol was added and shaken. The solution was centrifuged at 15,000 g for 
15 minutes and the supernatant was removed. After the pellet of deoxy-
ribonucleic acid (DNA) had dried, it was dissolved in 100 μl of Tris-eth-
ylenediaminetetraacetic acid (TE-EDTA) solution (Tris 1 mM, EDTA 
100 μM, pH 8.2). The nucleic acids were stored at -20 °C until use.
Roche Linear Array®
The Roche Linear Array® (LA) HPV genotyping assay (Roche Mo-
lecular Systems, Alameda, California, United States) is based on poly-
merase chain reaction (PCR) amplification of the target DNA using 
HPV primers (PYGM09/11), hybridization of the amplified product 
using oligonucleotide probes and then their detection using a colori-
metric reaction. The master mix contains primers for amplification of 
a 450-base pair (bp) fragment of the L1 region of more than 37 HPV 
genotypes18 and a 268-bp fragment of the human β-globin gene, as an 
internal control. 
Detection and genotype determination were performed using the de-
natured amplified DNA and an array of oligonucleotide probes located 
in the polymorphic region of L1. This enabled independent identifica-
tion of 37 individual HPV genotypes (Figure 1), as follows: 16 high-risk 
HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73 and 
82), 11 low-risk HPV types (6,11, 40, 42, 54, 61, 70, 72, 81, CP6108 
and 67), two intermediate-risk HPV types (26 and 53) and eight HPV 
types of undetermined risk (55, 62, 64, 69, 71, 83, 84 and IS 39).
Statistical methods
The data were tabulated in OpenOffice spreadsheets and analyzed 
in the R environment for statistical analyses. The proportions of CIN 2 
and CIN 3 in groups of women infected with various A7 and A9 phylo-
genetic HPV groups were compared using Fisher’s exact test. Three situ-
ations were considered: women with single infections; multiple infec-
tions; and the whole sample. A linear regression model was then fitted 
to assess the proportions of CIN 2 and CIN 3 in groups of women with 
different single or multiple combinations of infecting HPV types.
RESULTS
The distribution of HPV types as single and multiple infections is 
shown in Table 1. Of the 37 HPV types included in LA-HPV, 32 were 
detected in the samples analyzed. HPV 16 was the most prevalent gen-
otype (present in 57.1% of the samples), either as a single infection or 
co-infecting the cervix together with other HPV types. It was the only 
infecting type in 15.2% of the samples. Other frequent genotypes, in ei-
ther multiple or single infections, were HPV 58 (26/105; 24.7%), HPV 
33 (16/105; 15.2%), HPV 52 (14/105; 13.3%), HPV 31 (11/105; 
10.4%) and HPV 51 (8/105; 7.6%), which are all high-risk HPV types. 
HPV 18 appeared in only 6.6% of the lesions, and it was not a single 
agent in any of them. Only 3/105 (2.87%) of the women had infections 
composed exclusively of low and intermediate-risk HPV types (as either 
single or multiple types). The precise composition of the various mul-
tiple HPV infections is shown in Figure 1. 
Multiple infections were detected in 68/105 (64.7%) of the wom-
en. The majority of these multiple-type infections included two 
HPV types (39/68; 57.3%). Considerably less frequently, there were 
three types (17/68; 25%), four types (8/68; 11.7%), five types (2/68; 
2.9%) and even six types (2/68; 2.9%) (data not shown). Among the 
multiple-type infections, 42/68 (61.7%) consisted exclusively of high-
risk HPV types. The predominant multiple-type associations (Figure 2) 
were HPV 16/58 with or without other types (n = 14), followed by HPV 
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Figure 1. Linear array strips for all cases, aligned with the reference card.
16/52 with or without other types (n = 8), HPV 16/18 with or without 
other types (n = 5), HPV 16/33 with or without other types (n = 4) and 
HPV 33/58 and HPV 35/52 with or without other types (n = 2, each). 
The distribution of HPV types in accordance with their phyloge-
netic species (genus Alpha, species 7: HPV 18, 39, 45, 59, 68, 70 and 
85; and genus Alpha, species 9: HPV 16, 31, 33, 35, 52, 58, and 67) 
in CIN 2 and CIN 3 lesions is shown in Table 2. The majority of the 
women had an HPV type of species Alpha 9 and others, while very few 
had Alpha 7 and others (5/105). There were 22 women (22/105) with 
both species (Alpha 9 and Alpha 7). Proportionally, women not infect-
ed with HPV species Alpha 9 were less likely to have CIN 3, compared 
with their Alpha 9 HPV-infected counterparts (P = 0.01). This tendency 
was also found when analyzing the subset of women with multiple in-
fections only (P = 0.001). In women infected with a single HPV type, 
the proportion of CIN 3/CIN 2 was the same, regardless of the HPV 
species present in their cervix (P = 0.20). 
The overall detection of HPV by LA was 105/106 women (99%); 
for CIN 2 it was 100% and for CIN 3 it was 99%. The HPV 16 and 
18 single infections, HPV 16/18 co-infections and HPV single or mul-
tiple infections without HPV 16 and 18 are summarized in Table 3. 
Infections including HPV 16 and 18 singly or in association with oth-
er HPV genotypes were significantly more common in CIN 3 than in 
CIN 2 (P = 0.01). 
DISCUSSION
In this study using the Roche LA-HPV genotyping assay, HPV was 
detected in 99% of CIN 2 and CIN 3 samples. Similar results were re-
ported by Castle et al.19 and Gargiulo et al.20 LA-HPV is a commercial 
HPV test, manufactured following good manufacturing practices with 
standardized reagents.19 In this assay, the same amplicon can be directly 
used for both detection of β globin and 37 different HPV genotypes in 
a single reaction. In the present series, this method was easy to use and 
highly accurate for detecting the majority of clinically significant HPV 
genotypes.
Unlike DNA sequencing, LA-HPV is capable of identifying multi-
ple infections.21,22 In the present series, 64.7% of the samples had mul-
tiple HPV genotypes. This high prevalence of multiple infections is evi-
dent in most studies using LA-HPV, ranging from 49.7% to 79.0%.20-22 
Detection and genotyping of HPV becomes more complex in samples 
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Single n (%) Multiple n (%) Total n (%)
CIN 2 CIN 3 CIN 2 CIN 3 CIN 2 CIN 3
A9 and others 
(except A7) 
1 (20) 29 (88) 8 (61) 34 (62) 9 (50) 63 (72)
A7 and others 
(except A9)
2 (40) 0 1 (8) 2 (4) 3 (17) 2 (2)
A9 and A7 0 0 3 (23) 19 (34) 3 (17) 19 (22)
Only others 2 (40) 4* (12) 1 (8) 0 3 (17) 4 (4)
Total 5 (100) 33 (100) 13 (100) 55 (100) 18 (100) 88 (100)
P = 0.20 P = 0.001 P = 0.01
Table 2. Distribution of human papillomavirus (HPV) genus A, species 7 
and 9 genotypes in cervical intraepithelial neoplasia (CIN 2 and CIN 3) 
among Brazilian women
A9 including 16, 31, 33, 35, 52, 58 and 67; A7 including 18, 39, 45, 59, 68, 70 and 85
*One CIN 3 HPV was HPV negative according to the Linear Array®







Multiple infections including HPV 16 and/or 18 6 (33) 40 (45)
Single infections including HPV 16 and/or 18 0 16 (19)
Multiple infections including neither HPV 16 nor 18 7 (39) 15 (17)
Single infections including neither HPV 16 nor 18 5 (27) 16 (19)
Total 18 (100) 87 (100)
One CIN 3 HPV was HPV negative according to the Linear Array® (not included in the table)
Table 3. Occurrence of human papillomavirus (HPV 16 and HPV 18) in 
cervical intraepithelial neoplasia (CIN 2 and CIN 3) in Brazilian women
Figure 2. Most prevalent associations of human papillomavirus (HPV) 





16-58 with or without other
16-18 with or without other
33-58 with or without other
16-52 with or without other
16-33 with or without other
35-52 with or without other
containing multiple genotypes, because of competition for reagents dur-
ing amplification and discrimination of the types amplified by PCR. 
The correlation between the numbers of additional types detected with 
LA-HPV suggests that less competition during amplification was en-
countered with LA-HPV.23
One clear advantage of full HPV genotyping is the ability to increase 
the performance of screening programs using HPV, while identifying the 
HPV-positive women who have persistent oncogenic HPV. There is some 
recent evidence that the risk of developing the lesion increases with the 
cumulative number of HPV types, and these associations seemed particu-
larly strong during the first year of follow-up.16 Thus, detection of short-
term HPV persistence may increase the specificity of the screening based 
on HPV. If full genotyping is introduced into the screening, the question 
of how often women who repeatedly test positive for oncogenic HPV 
(with or without HPV 16 and HPV 18) present persistent oncogenic 
HPV infection can be resolved.24 However, it should be emphasized that 
current guidelines on cervical screening suggest that HPV testing should 
be used at intervals no shorter than three years, which offsets the applica-
bility of HPV genotyping, in the form described above.
In this series of Brazilian women, the overall prevalence of HPV 16 
was 57.1%, although HPV 16 as a single type was present only in 15.2% 
of the cases. The associations most frequently found were of HPV 16 to-
gether with HPV 58, 52, 18 and 33. In a study very similar to the pres-
ent one, in terms of design, Prétet et al.25 examined a sample of CIN 2 
and 3 and found that HPV 16 was the most frequent type. However, in 
contrast to the present findings, that type was the only agent in 40.4% 
of the samples. In a recent meta-analysis, Smith et al.8 found that the 
prevalence of HPV 16 (both single and co-infections) in high-grade le-
sions collected from all around the world was 45.3%. 
In our study, the HPV 18 genotype appears in seventh position in 
terms of prevalence, occurring in 6.6% of the samples. Invariably, HPV 
18 was associated with other HPV genotypes. This is very similar to the 
report by Prétet et al.,25 with HPV 18 prevalence of 4.3% (6.6% of 121 
CIN 2 lesions and 3.5% of 372 CIN 3 lesions) and only three CIN 3 le-
sions presented HPV 18 as the single type of infection. In the report by 
Smith et al.,8 HPV 18 appears in fifth position with an overall prevalence 
of 6.9%. There are some minor differences between this meta-analysis8 
and our results, regarding the order of prevalence of the most common 
HPV genotypes: 16, 31, 33, 58, 18, 52, 35 and 51 in the meta-analysis; 
and 16, 58, 33, 52, 31, 51, 18 and 68 in the present series. However, 
these authors stated that there was an important lack of South American 
data in their meta-analysis, and our present study adds new information 
concerning the HPV type distribution in high-grade lesions among Bra-
zilian women. 
Comparing CIN 2 and CIN 3, HPV 16 and 18 were significantly 
more prevalent in CIN 3 lesions. This is consistent with the data of Pré-
tet et al.,25 who analyzed 121 CIN 2 and 372 CIN 3 lesions in France, 
and also found higher prevalence of HPV 16 in CIN 3 (64.2%) than 
in CIN 2 lesions (56.2%). This difference was even more marked in a 
study by Zuna et al.,9 who reported HPV 16 infection in 65.6% of CIN 
3 and only 19.0% in CIN 2 lesions. Despite the fact that in all report-
ed series, CIN 2 lesions represented a minority of cases, these data sug-
gest that CIN 2 and 3 might differ in their biological potential, and that 
HPV genotypes might interfere with the risk of progression in these two 
categories of CIN lesions. 
According to the results from the present study, women infected 
with Alpha 9 species were more likely to have CIN 3 than were women 
infected with Alpha 7 species and others. These data are compatible with 
the information on the carcinogenic potential of specific HPV types. In 
fact, studies have demonstrated that HPV 16, 18 and 45 are more prev-
alent in squamous cell carcinoma than in HSIL (CIN 2 and CIN 3), 
whereas the reverse is true for other oncogenic types, including HPV 31, 
33, 52 and 58. Infection with HPV 16 imposes the highest risk of both 
CIN 3 and cervical carcinoma, although HPV 33, which also belongs to 
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the Alpha 9 species, possibly has a greater oncogenic potential than HPV 
18 and 45.7 In another epidemiological study, Wheeler et al.26 observed 
a higher risk of CIN 3 among women with HPV 31 (Alpha 9) and rela-
tively low oncogenic potential for HPV 56 and 59 (Alpha 7).
The present study provides new information on the distribution of 
individual HPV genotypes and multiple infections, obtained using the 
Roche LA-HPV assay. These data suggest that a prophylactic vaccine 
against HPV 16/18 has the potential to prevent approximately half of 
the high-grade lesions. For one of the two candidate vaccines, Harper 
et al.27 stated that this proportion might even be increased, if cross-pro-
tection were achieved against some other high-risk HPV types, e.g. total 
protection against HPV 45, partial protection against HPV 31 and no 
protection against HPV 33, 52 and 58. However, the full implications 
of this observation are difficult to define, because HPV 45 was under-
represented in our cohort, in the same way as in the recent meta-analy-
sis.8 These data on HPV genotype distribution among different popula-
tions are of crucial importance for designing second-generation prophy-
lactic HPV vaccines in the near future. Also of relevance, future thera-
peutic HPV vaccines would have greater potential benefit if their design 
for treating HPV infections were not restricted to HPV 16 and 18. The 
best hypothetical scenario is one in which vaccine constituents are cho-
sen taking into consideration the epidemiological distribution of HPV 
types in the specific geographical regions where they are to be used.
CONCLUSIONS
The present series firmly corroborates the assumption that, in most 
CIN 2 and CIN 3 cases, multiple high-oncogenic HPV types may be 
found. In our series, the prevalence of HPV 58 and HPV 33 was unex-
pectedly high. CIN 3 was typically associated with HPV genus Alpha, 
species 9, most often consisting of types 16 and 58, alone or in combi-
nation with other HPV types.
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